J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'

Nicole DeFeudis

Editor

Putting a damper on a years-long kinship, J&J says it’s partly backing out of two license agreements for Alkermes’ nanoparticle technology, which the pharma giant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'

Nicole DeFeudis

Editor

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

J&J tries to back out of nanopar­ti­cle li­cense agree­ment — but Alk­er­mes says 'not so fast'

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus